Literature DB >> 6254599

Effects of RMI 12330A, a new inhibitor of adenylate cyclase on myocardial function and subcellular activity.

G Grupp, I L Grupp, C L Johnson, M A Matlib, W Rouslin, A Schwartz, E T Wallick, T Wang, P Wisler.   

Abstract

1 RMI 12330A, a lactam-imine, at concentrations of 10(-4) M and higher, inhibited basal as well as isoprenaline and NaF-stimulated adenylate cyclase activity of guinea-pig heart homogenates. However, RMI 12330A was a more potent inhibitor of histamine-stimulated adenylate cyclase (IC50 of 1.5 X 10(-5) M). 2 In the isolated work-performing heart of the guinea-pig, RMI 12330A (IC50 of 1.1 X 10(-6) M) depressed all cardiac functions: pressures developed, dP/dt, contractile force, dF/dt, work performance and stroke work. Left atrial pressure rose and the positive inotropic response to increasing heart rate (staircase) became negative. Histamine, isoprenaline and ouabain no longer caused positive inotropic effects. 3 Increasing the perfusate calcium concentration from 2.5 mM to 4.5 and 6.5 mM completely restored cardiac function after its depression by RMI 12330A. 4 RMI 12330A uncoupled mitochondrial oxidative phosphorylation; the classical uncoupler, dinitrophenol, had the same effects on cardiac dynamics as RMI 12330A. 5 RMI in high doses inhibited hydrolytic activity of Na+, K+-ATPase of crude and purified heart preparations (IC50 of 1.7 X 10(-4) M) and inhibited ouabain binding to the same enzymes (IC50 of 1.5 X 10(-4) M). 6 A lactam-imine analogue of RMI 12330A that had no effect on adenylate cyclase, was also without effect on any of the systems examined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254599      PMCID: PMC2044352          DOI: 10.1111/j.1476-5381.1980.tb08721.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Effect of temperature on phosphorylation and ouabain binding to N-ethylmaleimide-treated (Na+, K+)-ATPase.

Authors:  E T Wallick; B M Anner; M V Ray; A Schwartz
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

2.  Isolation of a unique peptide inhibitor of hormone-responsive adenylate cyclase.

Authors:  G S Levey; D C Lehotay; J M Canterbury; L A Bricker; G J Meltz
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

3.  Cyclic AMP-enhanced protein phosphorylation and calcium binding in a cell membrane-enriched fraction from myocardium.

Authors:  E G Krause; H Will; B Schirpke; A Wollenberger
Journal:  Adv Cyclic Nucleotide Res       Date:  1975

4.  Cyclic changes in levels of cyclic AMP and cyclic GMP in frog myocardium during the cardiac cycle.

Authors:  A Wollenberger; E B Babskii; E G Krause; S Genz; D Blohm; E V Bogdanova
Journal:  Biochem Biophys Res Commun       Date:  1973-11-16       Impact factor: 3.575

5.  Cyclic adenosine 3',5'-monophosphate-dependent protein kinase stimulation of calcium uptake by canine cardiac microsomes.

Authors:  M A Kirchberger; M Tada; D I Repke; A M Katz
Journal:  J Mol Cell Cardiol       Date:  1972-12       Impact factor: 5.000

6.  Adrenergic receptors for metabolic responses in adipose tissue.

Authors:  J Himms-Hagen
Journal:  Fed Proc       Date:  1970 Jul-Aug

7.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

8.  Possible cyclic nucleotide regulation of calcium mediating myocardial contraction.

Authors:  A Schwartz; M L Endman; E G Ezrailson; D C Lehotay; G Leyey
Journal:  Science       Date:  1977-03-11       Impact factor: 47.728

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Localization of beta adrenergic receptors, and effects of noradrenaline and cyclic nucleotides on action potentials, ionic currents and tension in mammalian cardiac muscle.

Authors:  H Reuter
Journal:  J Physiol       Date:  1974-10       Impact factor: 5.182

View more
  8 in total

Review 1.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

2.  The effects of an adenylate cyclase inhibitor on the electrophysiological correlates of neuromuscular transmission in the frog.

Authors:  E M Silinsky; S M Vogel
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

3.  Parallel pathways mediate inhibitory effects of vasoactive intestinal polypeptide and nitric oxide in canine fundus.

Authors:  O Bayguinov; K D Keef; B Hagen; K M Sanders
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

4.  Evidence that the presynaptic A2a-adenosine receptor of the rat motor nerve endings is positively coupled to adenylate cyclase.

Authors:  P Correia-de-Sá; J A Ribeiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

5.  Pharmacological distinction between soluble and transmembrane adenylyl cyclases.

Authors:  Jacob L Bitterman; Lavoisier Ramos-Espiritu; Ana Diaz; Lonny R Levin; Jochen Buck
Journal:  J Pharmacol Exp Ther       Date:  2013-10-03       Impact factor: 4.030

6.  On the mechanism by which adenosine receptor activation inhibits the release of acetylcholine from motor nerve endings.

Authors:  E M Silinsky
Journal:  J Physiol       Date:  1984-01       Impact factor: 5.182

7.  Effects of oxotremorine and RMI 12330 A on [3H]acetylcholine release and adenylate cyclase activity in guinea pig superior cervical ganglion.

Authors:  A Capuzzo; P G Borasio; E Fabbri
Journal:  Neurochem Res       Date:  1988-11       Impact factor: 3.996

8.  Contributions of cardiac "funny" (f) channels and sarcoplasmic reticulum Ca2+ in regulating beating rate of mouse and guinea pig sinoatrial node.

Authors:  Islom B Nazarov; Christopher J Schofield; Derek A Terrar
Journal:  Physiol Rep       Date:  2015-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.